WebJul 28, 2024 · McGuireWoods LLP represented Cleveland BioLabs and Troutman Pepper Hamilton Sanders LLP represented Cytocom in the merger. About Cytocom Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary … WebJul 6, 2024 · During the call, Michael K. Handley, President and Chief Executive Officer of Cytocom, and members of the Cleveland BioLabs Board of Directors will discuss the results of the vote on the merger transaction, scheduled to take place July 6, 2024, during a Special Meeting of Cleveland BioLabs shareholders.Mr. Handley will also discuss the …

Cytocom and Cleveland BioLabs Announce Definitive Merger …

http://www.cbiolabs.org/cbl0137/ WebJul 28, 2024 · McGuireWoods LLP represented Cleveland BioLabs and Troutman Pepper Hamilton Sanders LLP represented Cytocom in the merger. About Cytocom Cytocom, … mountainboard next

ENTOLIMOD (CBLB502) BIODEFENSE Cleveland Bio Labs

WebOct 19, 2024 · Cleveland BioLabs discusses many of these risks in Item 1A under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its other filings ... WebJul 27, 2024 · Combined company will continue to be listed on the Nasdaq under the name Cytocom, Inc. with the proposed ticker symbol “CYTO”. In case of termination, Cleveland BioLabs will pay a fee of $0.3 million to Cytocom and Cytocom will pay a fee of $0.2 million to Cleveland BioLabs. WebAbout Cleveland BioLabs ( CBLI) Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. mountainboard kheo kicker